Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Philip on FOLFIRINOX in Locally Advanced Pancreatic Cancer

May 9th 2019

Philip A. Philip, MD, PhD, FRCP, professor, Department of Oncology, Karmanos Cancer Institute, discusses the use of FOLFIRINOX in patients with locally advanced pancreatic cancer.

Vaccine Shows Signs of Stimulatory Effects in Early-Stage CRC

May 8th 2019

A vaccine targeting GUCY2C, a commonly overexpressed protein in patients with early-stage colorectal cancer, induced antibody and T-cell responses toward the specified target and demonstrated an acceptable safety profile in this patient population

Navigating the Complexities of Tumor Sidedness in Colorectal Cancer

May 7th 2019

Scott Kopetz, MD, PhD, FACP, explains the biologic difference between left- and right-sided colorectal cancer and highlights recent research on tumor sidedness and its impact on clinical practice.

Systemic Treatments for NETs: Whom to Treat and How to Sequence

May 2nd 2019

During a recent panel discussion, neuroendocrine tumor experts Simron Singh, MD, MPH, and Jonathan R. Strosberg, MD, provided insight on which patients are the best candidates for these approved treatments and how to sequence therapy to optimize outcomes.

Dr. Anthony on Sequencing Strategies for Patients With NETs

May 2nd 2019

Lowell B. Anthony, MD, FACP, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses sequencing strategies for patients with gastroenteropancreatic neuroendocrine tumors.

Dr. Mahipal on Molecular Markers in mCRC

May 2nd 2019

Amit Mahipal, MBBS, senior associate consultant, Division of Medical Oncology, Department of Oncology, associate professor of oncology, Mayo Clinic, discusses emerging molecular markers in patients with metastatic colorectal cancer (mCRC).

NETs Treatment Arsenal Expands, With More Progress on the Horizon

May 1st 2019

Lowell B. Anthony, MD, FACP, sheds light on important data that have shaped the current neuroendocrine tumors treatment paradigm and highlights notable ongoing studies.

Dr. Kim on the Potential of Ramucirumab in Advanced HCC

April 26th 2019

Richard Kim, MD, assistant professor of oncology at University of South Florida College of Medicine, medical oncologist in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses the potential of ramucirumab in the treatment of advanced hepatocellular carcinoma.

Dr. Overman on Tailoring Approaches to Molecular Subsets in mCRC

April 26th 2019

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses tailoring approaches to molecular subsets of patients with metastatic colorectal cancer.

Pembrolizumab/Chemo Combo Misses OS Endpoint in Advanced Gastric/GEJ Cancer

April 26th 2019

The combination of pembrolizumab (Keytruda) and chemotherapy did not improve overall survival or progression-free survival compared with standard chemotherapy alone for the frontline treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Dr. O'Hara on the Rationale for APX005M in Combination With Chemotherapy and Nivolumab in Pancreatic Cancer

April 26th 2019

Mark H. O’Hara, MD, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the rationale for evaluating APX005M in combination with chemotherapy and nivolumab (Opdivo) in pancreatic cancer.

Dr. Binder on Data Regarding Rucaparib Maintenance in Pancreatic Cancer

April 25th 2019

Kim A. Reiss Binder, MD, assistant professor of medicine in the Division of Hematology Oncology at the University of Pennsylvania, discusses data on maintenance therapy with rucaparib (Rubraca) in patients with pancreatic cancer.

Dr. Mizrahi on the Importance of Personalized Care in mCRC

April 24th 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of personalized care in patients with metastatic colorectal cancer.

Dr. Ku on Role of Durvalumab in Gastric Cancer

April 24th 2019

Geoffrey Y. Ku, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of durvalumab in the treatment of patients with gastric cancer.

New VENTANA HER2 ISH DNA Assay Launches for Breast, Gastric Cancers

April 23rd 2019

A new VENTANA HER2 dual in situ hybridization companion diagnostic assay has launched to identify HER2 amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab.

Dr. Ciombor Discusses Role of Liquid Biopsies in CRC

April 22nd 2019

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the role of liquid biopsies in colorectal cancer.

SM-88 May Fill Unmet Need in Pancreatic Cancer

April 22nd 2019

Marcus Smith Noel, MD, discusses the early promise of SM-88 in the metastatic pancreatic cancer treatment landscape.

Dr. Overman on Unmet Needs With Immunotherapy in mCRC

April 19th 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses unmet needs with immunotherapy in metastatic colorectal cancer.

Tailored Approaches Offer Curative Potential to CRC Subsets

April 19th 2019

Michael J. Overman, MD, discusses an immunotherapy combination regimen in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.

Dr. Tempero on Role of Molecular Profiling in Pancreatic Cancer

April 18th 2019

Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, Rombauer Family Distinguished Professor in Pancreas Cancer Clinical and Translational Science, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of molecular profiling in pancreatic cancer.